Recombinant techniques allow one to engineer an antibody molecule and, in this way, manipulate its properties and functions. We engineered a chimeric human/ mouse antibody to the tumor-associated antigen ganglioside GD2, with the aim ofdecreasing its serum half-life, maintaining its full antigen-binding capacity, and deleting its effector functions, thus making it a potentially useful reagent for the radioimaging of tumors. To this end, the constant region of the human yl chain was mutated by deleting the second domain (CH2). Here we show that the Cn2-deleted antibody (ch14.18-ACH2) was cleared from the blood of athymic (nu/nu) mice bearing human melanoma tumors with the same kinetics as human IgG F(ab')2. At a 3 t1/, of 12 hr, 0.9% of the inected dose of 'MI-labeled chl4.18-ACH2 was found per milliliter of blood 24 hr after i.v. injection. In biodistribution experiments, '25I-labeled chl4.18-ACH2 targeted specifically to melanoma xenografts, achieving optimal tumor-to-tissue ratios 12-16 hr after i.v. injection. chl4.18-ACH2 was localized to the melanoma tumors more rapidly and with better localization ratios than the intact chimeric antibody chl4.18. Sixteen hours after i.v. injection, the tumor-to-blood and tumor-to-liver ratios of chl4.18-ACH2 were 5 and 12, respectively, while optimal localization ratios obtained for chl4.18 were 1 and 5, respectively, but 96 hr after injection. A reagent such as ch14.18-ACH2 should be useful for radioimmunodetection of human tumors because of reduced immunogenicity, increased targeting specificity, and rapid clearance from circulation.
Radiolabeled monoclonal antibodies (mAbs) against tumorassociated antigens have been shown to localize specifically to melanoma and other solid tumors and can be used in radioimmunoimaging for the identification of occult lesions (1) (2) (3) . For tumor imaging, it is advantageous to use antibody fragments instead of intact antibodies, because fragments clear faster from circulation and have a better tumor accessibility due to their smaller size. This has been found in experimental animals (4-6) as well as in cancer patients (7) . Recombinant DNA techniques make it possible to engineer the antibody molecule and to obtain antibodies with novel properties and functions (8, 9) . For use in human therapy, murine variable regions and human constant regions can be fused to construct chimeric antibodies that are considerably less immunogenic in man than murine mAbs (10) . Also, site-directed mutagenesis in the variable region of a mAb can result in an antibody with higher affinity and specificity for its antigen (11) , and exchanging constant regions of a mAb can improve its ability to mediate effector functions, such as complement-mediated cytotoxicity and antibody-dependent cytotoxicity by effector cells (12, 13) . On the other hand, digestion with proteolytic enzymes is not applicable to all mAbs. If active fragments can be produced, this technique can be limited by problems such as low yield, contamination with enzyme, and others (14, 15) . Therefore, our aim was to generate a mutant antibody with characteristics of a F(ab')2 fragment that is useful for tumor imaging.
Earlier, we described the development of a chimeric human/mouse antibody, chl4.18, directed against the disialoganglioside GD2, an antigen expressed on human tumors of neuroectodermal origin (16) . chl4.18 was used to study the effects of mutating and deleting the constant regions of the human yl chain. Although it was not possible to engineer a functional F(ab')2 of chl4.18 [i.e., a mutant missing the second and third domains ofthe constant region ofthe human yl chain (CH2 and CH3) (17)], we were able to express an antibody that was deleted of CH2. The mutant antibody deleted of CH2 (chl4.18-ACH2) was characterized and compared with the intact chimeric antibody. By gel electrophoresis on SDS gels and by high-pressure exclusion chromatography under nondenaturing conditions, chl4.18-ACH2 appeared to have a molecular mass of 120 kDa. chl4.18-ACH2 bound to purified ganglioside GD2; however, unusual binding characteristics of chl4.18-ACH2 were observed in that it competes much more efficiently with chl4.18 for antigen than does chl4.18 with itself, especially at short incubation times. This is thought to reflect some conformational changes in the overall structure of the molecule rather than in binding affinity (17) . In contrast to chl4. 18 (13) . After a 1-hr incubation, both antibodies stained all cells with the same intensity (Fig. 1) , indicating no differences in the binding of the intact and mutant chimeric antibody to tumor cells.
In nude mice bearing M21 tumors, 125I-labeled chl4.18-A&CH2 (1251-chl4.18-ACH2) was cleared very rapidly from the intravascular compartment (Fig. 2) . The The biodistribution of 125I-chl4.18-ACH2 in nude mice with human melanoma tumors is shown at different time points in Fig. 4 . The amount ofradioactivity in the s.c. tumors was the highest at the first time point after i.v. injection, reaching 14.8% of the injected dose per gram of tumor after 4 hr and dropping to 2.8% after 24 hr. At later time points, the selectivity of the localization increased as 125I-chl4.18-ACH2 was eliminated more slowly from the tumor than from blood and the other organs. The biodistribution of 1251-chl4.18-ACH2 was compared with that of the same amount of labeled intact antibody chl4.18 (Fig. 5) . In addition to the 4-and 24-hr time points, the biodistribution after 4 days is also shown, because the intact antibody chl4.18 was cleared much more slowly from the blood than chl4.18-ACH2 and the tumorto-tissue ratios improved at later time points. For 125I-chl4.18, the highest uptake of radioactivity into the tumor was not found at the earlier time points but was found 24 hr after i.v. injection. Twenty-four hours after injection, the amount of 125I-chl4.18 per gram of tumor was 3.5-fold higher than that of 1251-chl4.18-ACH2. However, the ratio of cpm in the tumor to cpm either in the surrounding tissue (skin) or in major organs (liver) was clearly better for chl4.18-ACH2 than for chl4.18. As shown in Table 1 between 12 and 16 hr after i.v. injection, whereas ch14.18 showed the best ratio after 96 hr. The CH2-deleted mutant antibody, chl4.18-ACH2, localized to human tumor xenografts in athymic (nu/nu) mice more rapidly and with better ratios than the intact chimeric antibody.
DISCUSSION
In this study, we show that CH2-deleted chimeric antibody was cleared from the blood oftumor-bearing athymic (nulnu) mice with the same kinetics as human IgG F(ab')2 and much faster than the corresponding intact chimeric antibody. The deletion mutant targets human melanoma xenografts in these mice specifically. It also localizes to the tumors more rapidly and with better localization ratios than the intact antibody.
The immunoglobulin molecule is divided into globular domains, and many of its functional properties can be localized to specific domains. The structural domains of the protein are encoded for by exons of the immunoglobulin genes. For the mutant antibody studied here, the CH2 exon was deleted from the human Cyl gene and was used subsequently to produce a human/mouse chimeric antibody with specificity for the tumor-associated antigen ganglioside GD2. Blood clearance of the CH2-deleted mutant antibody was studied in athymic (nu/nu) mice bearing human tumor xenografts, as it was shown previously that murine and chimeric human/mouse antibodies have identical pharmacokinetics in this model system (13, 19) . The mutant antibody was cleared more rapidly from the blood of these mice. Clearance of F(ab')2 fragments of murine mAbs has been reported to be similar to what we describe here for the CH2-deleted mutant antibody and human F(ab')2 fragments (20, 21) . The CH2- deleted mutant and the intact chimeric antibody were both expressed and produced in a murine hybridoma cell line. An obvious difference between the two mAbs is that the intact chimeric antibody is glycosylated, while the mutant lacking Asn-297, the sole site for N-linked glycosylation, is not. Therefore, it could be argued that the rapid elimination of the mutant antibody is due to the lack of carbohydrate side chains rather than to the deletion of the whole CH2 domain. In this regard, plasma clearance of proteolytic fragments of human myeloma IgG has been studied in rabbits (22) . A half-life of about 70 hr was found for whole IgG, Fc, and CH2 fragments, while Fab and CH3 fragments were eliminated with a half-life of 16 hr. Furthermore, carbohydrate-deficient antibodies have been generated by mutating the Asn-297 in the CH2 region of another human/mouse chimeric antibody of the IgG1 isotype (23) . No difference in blood clearance was found between the aglycosylated and the intact chimeric antibody in mice. Taken together, these findings and our data suggest that it is the CH2 domain and the influence it has on the conformation of the whole molecule rather than the carbohydrate side chains that provides the dominant factor controlling the catabolic rate of IgG.
The CH2-deleted antibody chl4.18-ACH2 was able to localize specifically to GD2' tumors. Twelve to 16 hr after injection, tumor-to-tissue ratios for the mutant antibody were optimal and higher at any time point than those observed with the intact chimeric antibody. Another advantage of the CH2-deleted antibody as a potential imaging reagent is the fact that it is able to leave the vascular space and to bind to the tumor cells more rapidly than the intact chimeric antibody, suggesting that it is a less rigid molecule. The improvement of tumor uptake ratios achieved by the CH2-deleted antibody is similar to that described by others, when comparing F(ab')2 fragments with whole murine mAbs (5, 6, 20, 21) . Rapid tumor localization and good localization ratios are properties that make CH2-deleted antibodies good candidates for radioimaging of tumors, possibly allowing the use of radioisotopes with low energy and a short half-life, such as 1231I or 991Tc (24, 25) . The use of CH2-deleted antibodies to deliver cytotoxic agents such as toxins, drugs, or radionuclides for therapy may be limited by its fast elimination; however, a possible exception may be the targeting of a-particle-emitting radionuclides such as 212Bi or 211At, with half-lives of 61 min and 7.2 hr, respectively (26, 27 ).
In conclusion, by studying the pharmacokinetic properties of a CH2-deleted chimeric antibody, we demonstrated that the catabolic rate of the antibody molecule is controlled by the CH2 domain. At the same time, we engineered a molecule that because of its in vivo characteristics should prove useful for the radioimmunodetection of human tumors.
